Neurosense Therapeutics is trading 5.4% lower at $2.02, with broad market weakness a plausible contributor.
- In Friday trading, the Nasdaq fell 2.1% and the S&P 500 fell 1.3%; Neurosense’s decline was larger.
- No clear company-specific announcement explaining the move was identified. An October 29 announcement concerned a presentation of clinical and biomarker findings at the NEALS meeting on October 30; available reporting does not establish it caused the share move.